导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 0.22% | 2139/4773 |
| 近一周 | -1.58% | 550/5462 |
| 近一月 | -1.46% | 955/5421 |
| 近一季 | -4.79% | 1711/5209 |
| 近半年 | -10.55% | 3650/4920 |
| 近一年 | 3.34% | 1946/4366 |
| 近两年 | 27.53% | 2392/2954 |
| 近三年 | 19.15% | 1498/2253 |
| 成立以来 | 95.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
3.33% 749/4961 |
1.35% 3041/5312 |
- - |
- - |
| 2025 | 6.82% 2943/4813 |
-4.13% 3130/3635 |
1.02% 2497/4076 |
6.96% 3487/4524 |
3.12% 743/4813 |
| 2024 | 18.04% 630/3463 |
9.17% 142/2808 |
2.05% 409/3014 |
6.28% 2860/3129 |
-0.30% 1377/3463 |
| 2023 | 7.54% 141/2656 |
15.75% 206/2280 |
0.94% 261/2385 |
-2.97% 810/2515 |
-5.14% 1264/2655 |
| 2022 | -11.54% 246/2207 |
-10.24% 383/1919 |
2.56% 1285/2016 |
-9.10% 247/2113 |
5.71% 445/2208 |
| 2021 | 28.85% 79/1822 |
3.60% 170/1255 |
4.72% 851/1330 |
17.01% 68/1466 |
1.50% 902/1822 |
| 2020 | 12.82% 807/1250 |
-7.91% 580/1028 |
-0.01% 1011/1067 |
11.13% 476/1164 |
10.26% 604/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 富国中证央企创新驱动ETF联接A VS. 长安沪深300非周期A(740101) |